ACHN News and Press, Achison Inc Cl A From 05/17/19

Cray (NASDAQ: CRAY ) +17%  on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more ...

Achillion Pharmaceuticals (NASDAQ: ACHN ) is up  7%  premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized ...

- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company ...

BioCryst Pharmaceuticals ( BCRX ) caught my eye recently because of the company advancing an oral factor D inhibitor into the clinic – BCX9930. Complement inhibition is an area of interest for me and I’ve recently written an article on Achillion Pharmaceuticals ( ACHN ) w...

BLUE BELL, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Patent and Tra...

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 GAAP EPS of -$0.14 in-line. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- PNH combo Phase 2 trial interim data to be presented May 17, 2019 - - C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 - - Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa., May 09, ...

Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more ...

Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up  1%  premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor ; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas. ...